Directorio

We are doing this study to find out if a drug called pembrolizumab (the study drug) is a safe and effective option for people with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. We want to know if adding it to treatment with the usual drug for this type of cancer can improve results.

We are doing this study to find out the safety and effectiveness of Tumor Treating Fields (TTFields, 200 kHz) delivered by the Optune® device. We want to know if this experimental procedure can improve results for people who are being treated for GBM. We will compare how well this procedure works when it is given along with 2 different types of drug therapies.

This study has two parts. The first part tests different doses of a drug called EIS 12656 to learn about its safety and how the body handles it. The second part uses the best dose to study the drug in more people. You will be in the second part of the study. Doctors will do tests to see how your body and your cancer respond to the study drug. These tests may include physical exams, checking your vital signs, taking blood and urine samples, heart tests, scans, and tumor biopsies. You will also keep a diary to write down when you take the drug.

We are doing this study to test the safety and efficacy of elacestrant compared to standard of care therapy in people with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-) early breast cancer with a high risk of coming back. We want to compare the effect of elacestrant to standard of care therapy. We want to know which option is most helpful for patient in doing their normal day to day activities, and to assess what the study drug does to the tumor markers that can be measured in your blood.

In this study, people will get a special Medtronic pacemaker placed in their chest. This pacemaker uses special settings to test whether a pacing rate based on each person’s body and heart helps improve heart failure symptoms. After the device is placed, people are put into one of two groups by chance. One group gets personalized pacing based on their height and heart function. The other group gets very little pacing, used only as a backup if the heart rate drops too low. Most people and study staff will not know which group they are in during the first year so the results stay fair. People will return for checkups at 2, 6, 12, 14, 18, and 24 months, and then once a year. At these visits, they may have heart images, blood tests, ECGs, questionnaires, a six minute walk test, and pacemaker checks. After the 12 month visit, everyone in the group with minimal pacing will switch to personalized pacing, and the study will continue to check safety and benefits.

People in the study will get meals delivered to their homes from local groups. They’ll also agree to share what the experience was like for them.

We are doing this study to find out if an investigational drug called teclistamab (the study drug) is a safe and effective option for people who have multiple myeloma and have achieved at least a partial response to standard therapy. We want to know how well it works on its own and in combination with a standard drug called lenalidomide.